BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Drug Discovery

Restore Vision Reports Encouraging Phase I II Data For RV 001 Gene Therapy In Retinitis Pigmentosa

Phase I/II clinical trial interim results, out to 168 days, from the two RV-001 dosing cohorts with advanced Retinitis Pigmentosa are presented at key Ma...

May 02, 2026 | News

Genexine Advances First In Class SOX2 Targeting BioPROTAC GX BP1 With Strong Preclinical Anti Tumour Data

Genexine, Inc. (KOSDAQ: 095700), a clinical-stage biotechnology company, announced new preclinical data for its SOX2-targeting bioPROTAC candidate, G...

May 02, 2026 | News

Insilico Medicine Secures IND Clearance For Rentosertib Inhalation Solution To Advance Targeted IPF Therapy

Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy impr...

April 30, 2026 | News

Cordis Launches SELUTION SLR Drug Eluting Balloon In Japan For Peripheral Artery Disease

Cordis, a global leader in interventional cardiovascular technologies, today announces the launch and availability of the SELUTION SLR™ PTA Drug...

April 29, 2026 | News

Becton Dickinson and Company And Suttons Creek Partner To Streamline Combination Product Development

The collaboration brings together consulting, device agnostic testing, and drug delivery expertise to help pharmaceutical and biotech companies reduce risk...

April 29, 2026 | News

HanchorBio, Inc. Partners With Bloomberg To Strengthen Data Driven Biopharma Strategy

Expanding HanchorBio's data-enabled approach from molecule design to portfolio and market insight -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stag...

April 27, 2026 | News

Kyowa Kirin Co., Ltd. And Kura Oncology, Inc. Advance Ziftomenib With Japan Phase 2 Trial In NPM1 Mutated AML

Regulatory Filing in Japan Planned Following Clinical Trial Completion – Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura...

April 27, 2026 | News

Everest Medicines Reports Promising First In Human Data For Personalised mRNA Cancer Vaccine EVM16

Everest Medicines announced that the first-in-human (FIH) clinical trial data of EVM16, a proprietary personalized mRNA cancer vaccine, were presen...

April 24, 2026 | News

ImmunoForge Advances CNS Drug Delivery With LMT15 Platform And Global Recognition

ImmunoForge's LMT15 Platform combines high BBB permeability with proprietary long-acting ELP technology Technology excellence validated by winning first...

April 23, 2026 | News

Leinco Technologies And CellCarta Partner To Advance Proteomics In Immuno Oncology

Leinco Technologies, a leader in antibody and protein development, and CellCarta, a global provider of precision medicine laboratory services, are ple...

April 22, 2026 | News

Biogen Inc. Secures Global Rights To Felzartamab Through Greater China Deal With TJ Biopharma

With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one...

April 22, 2026 | News

Mabwell Secures JFDA GMP Compliance For Denosumab Biosimilars, Marking PIC S Milestone

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its wholly-owned subsidiary, T-m...

April 22, 2026 | News

Orthogon Therapeutics Secures 11 Million Dollars To Advance First In Class Oral Therapy For BK Virus In Transplant Patients

Orthogon Therapeutics announced the closing of an $11 million follow-on financing, bringing the total capital raised to $36 million. The financing will ena...

April 21, 2026 | News

EpiBiologics Advances Tissue Selective EGFR Degrader EPI 326 Into First In Human Clinical Study

First-in-human study of EPI-326 will evaluate the company’s lead tissue-selective EGFR degrader in patients with NSCLC and HNSCC with potential to ...

April 21, 2026 | News

Stay Connected